Hyperlipidemias: Glesby MJ

  Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 3 Articles   Help
A digest of articles written 1999 and later, on the topic "Hyperlipidemias," originating from Planet Earth —» Glesby MJ.  Display:  All Citations ·  All Abstracts
1 Guideline Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. 2003

Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ, Anonymous00228, Anonymous00229. · Indiana University, Indianapolis, USA. · Clin Infect Dis. · Pubmed #12942391 No free full text.

This publication has no abstract.

2 Review Coronary heart disease in HIV-infected persons. 2003

Glesby MJ. · Cornell Clinical Trials Unit, Weill Medical College of Cornell University, New York, USA. · AIDS Read. · Pubmed #12762289 No free full text.

Abstract: Treatment of HIV-infected patients with HAART has prolonged survival, and clinicians must now be concerned with chronic diseases, some of which may be more prevalent in this population. This article focuses on coronary heart disease in persons with HIV infection.

3 Clinical Conference A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. 2005

Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ, Anonymous00493. · AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA. · AIDS Res Hum Retroviruses. · Pubmed #16218799 No free full text.

Abstract: There is a paucity of information on the safety and efficacy of lipid-lowering therapy for dyslipidemia associated with human immunodeficiency virus (HIV) and antiretroviral therapy. Our objective was to determine whether fenofibrate and pravastatin were equivalent for the treatment of combined dyslipidemia in HIV as measured by a composite of the National Cholesterol Education Project (NCEP) goals based on absolute values for low-density lipoprotein (LDL), triglycerides (TG), and high-density lipoprotein (HDL) and to compare the safety of these agents through 48 weeks. This was a randomized, open-label trial with subjects assigned to fenofibrate 200 mg (n = 88) or pravastatin 40 mg (n = 86) daily. Subjects who failed to reach the NCEP composite goal on monotherapy by week 12 received both drugs. The composite goal at week 12 was achieved in 1% of fenofibrate and 5% of pravastatin subjects. At week 16, 69/88 subjects on fenofibrate added pravastatin (FP) and 67/86 subjects on pravastatin added fenofibrate (PF). At week 48, 7% FP subjects and 3% PF subjects achieved the composite goal. Median changes in LDL/HDL/TG/non-HDL were -8/+5/-144/+50 and -14/+2/-66/+34 mg/dl in subjects receiving FP and PF, respectively. There were few adverse events and no rhabdomyolysis reported. Combination therapy with fenofibrate and pravastatin for HIV-related dyslipidemia provides substantial improvements in lipid parameters and appears safe, but is unlikely to achieve all NCEP targets for lipid levels.